ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2292

The Predictive Risk Factors for Opportunistic Infection during Immunosuppressive Therapy for Polymyositis/Dermatomyositis

Yumiko Sugiyama1, Ryusuke Yoshimi2, Maasa Tamura2, Mitsuhiro Takeno3, Yohei Kirino2, Shigeru Ohno4 and Hideaki Nakajima2, 1Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 2Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 4Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Clinical research, opportunistic infections and polymyositis/dermatomyositis (PM/DM)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Muscle Biology, Myositis and Myopathies Poster III: Treatment and Classification Criteria

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM), intensive immunosuppressive treatment are necessary for severe cases. We have already reported that high initial dose of glucocorticoid and combination immunosuppressive therapy for induction therapy, and KL-6 levels at the baseline were independent risk factors for infection. Here we investigated the predictive risk factors for opportunistic infection during immunosuppressive treatment for PM/DM by assessing cytomegalovirus (CMV) antigen test as a barometer for immunocompromised status.

Methods: We retrospectively analyzed clinical features, laboratory data at baseline in the patients with PM/DM who had received initial treatment at six hospitals affiliated to Yokohama City University from 2003 to 2016. We also investigated initial therapeutic regimens and clinical outcomes including CMV antigenemia as a complication. We conducted univariate and multivariate analyses to extract risk factors for CMV antigenemia.

Results: One hundred sixty-eight (PM 42, DM 82, and clinically amyopathic DM (CADM) 44) were recruited. The mean age was 56 ± 16 years and 120 (71.4%) were female. As initial therapies, oral prednisolone (PSL) was prescribed in all patients. Methylprednisolone (mPSL) pulse, intravenous cyclophosphamide (IVCY), and oral calcineurin inhibitor therapies were performed in 93 (56%), 50 (30%) and 86 (51%), respectively. Forty patients (24%) received combination therapy with IVCY and a calcineurin inhibitor. Fifty-two patients (31%) had CMV antigenemia within 6 months from initiation of immunosuppressant. An univariate analysis showed complication of ILD, high activity of ILD such as high KL-6 and low PaCO2 and strong immunosuppressive therapy tended to be positive CMV antigenemia (Table 1). There was no association between the cumulative PSL dose except within one month and CMV antigenemia. A multivariate logistic regression analyses revealed that low PaCO2 (p = 0.023, OR 0.78) and old age (p = 0.040, OR 1.07) were independent risk factors for CMV antigenemia. Moreover, the patients with positive CMV antigenemia tended to infected which were needed antibiotic therapy with significant differences (OR 4.52, p < 0.001). There were no patients with organ dysfunction as CMV infection.

Conclusion:

Although rapid and intensive therapies are required for PM/DM, appropriate monitoring, prophylaxis and early treatment for opportunistic infection are important, especially in patients who receive strong immunosuppressive therapy and who show low PaCO2 level and old age at baseline.


Disclosure: Y. Sugiyama, None; R. Yoshimi, None; M. Tamura, None; M. Takeno, Celgene Corporation, 2; Y. Kirino, None; S. Ohno, None; H. Nakajima, None.

To cite this abstract in AMA style:

Sugiyama Y, Yoshimi R, Tamura M, Takeno M, Kirino Y, Ohno S, Nakajima H. The Predictive Risk Factors for Opportunistic Infection during Immunosuppressive Therapy for Polymyositis/Dermatomyositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-predictive-risk-factors-for-opportunistic-infection-during-immunosuppressive-therapy-for-polymyositis-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-predictive-risk-factors-for-opportunistic-infection-during-immunosuppressive-therapy-for-polymyositis-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology